The Biochemical Bone Marker Market - Dawn or Dusk?
This article was originally published in Clinica
Biochemical bone marker tests, especially those for bone resorption, are on the brink of being established as a routine tool in the management of osteoporosis. Until two years ago, the new market of resorption tests was one of the fastest growing sectors in immunodiagnostics. Nonetheless, the share prices of the two main players - Metra Biosystems and Ostex International - have reached an all-time low of below $1.00.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.